CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Right now, both are “associated with recurrent abdominal pain and are among the most commonly diagnosed medical problems in pediatrics,” says Therapy. To treat it, many companies – and physicians will ...

Minot Light Capital Partners, an investment management company, released its "Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% ...

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company&CloseCurlyDoubleQuote ...

NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation ...

CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...

Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same ...

Shares of NeurAxis, Inc. NRXS have gained 13.3% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 4.3% growth over the same time frame.

. Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the“Company”) (NYSE American: ...